Thalassaemia trials in Greece

In Greece 8 Also abroad 73

8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Where
Athens, Thessaloniki
Age
1 year to 17 years
People
54 worldwide
Run by
Agios Pharmaceuticals, Inc.
See details and how to joinNCT07506863 · EU 2025-524707-71-00
Phase 3Taking people
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia
Where
Athens
Age
1 year to 17 years
People
45 worldwide
Run by
Agios Pharmaceuticals, Inc.
See details and how to joinNCT07517133 · EU 2025-524706-15-00
Phase 3Taking people
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Where
Athens, Larissa, Patras, Thessaloniki
Age
2 years and over
People
480 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00
Phase 2Taking people
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Where
Athens
Age
6 years to 17 years
People
99 worldwide
Run by
Celgene
See details and how to joinNCT04143724 · EU 2022-502499-22-00
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Athens, Rio Patras, Thessaloniki
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
No phaseEnrolling by invitation
Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia Patients
Where
Athens
Age
18 years and over
People
30
Run by
University Research Institute for the Study of Genetic & Malignant Disorders in Childhood
See details and how to joinNCT07055503
Phase 2Taking people
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Where
Athens, Chaïdári, Ioannina, Larissa, Patra, Thessaloniki
Age
18 years to 64 years
People
90 worldwide
Run by
Pharmacosmos A/S
See details and how to joinNCT05693909 · EU 2023-507396-21-00
No phaseTaking people
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Where
Athens, Larissa
Age
2 years and over
People
30,000 worldwide
Run by
Cyprus Institute of Neurology and Genetics
See details and how to joinNCT05799118